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We report the case of a middle age patient presenting with Tako-Tsubo cardiomyopathy (TTC) compli-
cated by cardiogenic shock that was successfully handled with milrinone. A 64-year old man presented
with cardiogenic shock after benzodiazepine and alcohol intoxication. A slight elevation of troponin and
typical left ventricular ballooning without coronary lesions suggested TTC. Within a few hours milrinone
infusion normalized the cardiac index. TTC is responsible for severe transient left ventricular dysfunction
occurring after physical or psychological stress. The major pathophysiological mechanism involved is
disproportionate catecholamine secretion, which may stun the myocardium. We considered if treatment
of this unique physiopathology with catecholamines could be dangerous in these patients and if alter-
native inotropes such as milrinone should be preferred.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Tako-Tsubo cardiomyopathy (TTC) is a recently identiﬁed entity
that is increasingly diagnosed to be responsible for severe transient
left ventricular dysfunction, usually occurring after psychological or
physical stress.1 TTC concerns preferentially post-menopausal
women but can also affects men.1 The prevalence of TTC is up to
7% of all suspected acute coronary syndromes in women and 1%
when both sexes are considered.2 This syndrome is characterized
by regional wall motion abnormalities, which mimic on ven-
triculography a Tako-Tsubo, i.e. a crock used in Japan to capture
octopuses. TTC presentation features signs of acute coronary syn-
drome but is not the consequence of obstructive coronary disease.1
This condition is considered to be related to disproportionate
catecholamine secretion, which may stun the myocardium.3 As a
result, catecholamine infusion can worsen the phenomenon and
therefore TTC presenting with cardiogenic shock is difﬁcult toBY-NC-ND license (http://
, Archet I University Hospital,
rance. Tel.: þ33 678992938;
06@free.fr (D. Doyen).
Published by Elsevier Inc. All righhandle. Cardiogenic shock complicates approximately 6.5% of TTC.4
Only a few data are available regarding the management of this
unique condition. Here we describe the successful treatment of a
patient presenting with Tako-Tsubo-related cardiogenic shock us-
ing milrinone, a non-catecholamine inotrope.
Case report
A 64-year old man was admitted for coma induced by benzo-
diazepine and alcohol intoxication. Endotracheal intubation was
performed to protect the upper airways. On admission, clinical
examination revealed skin mottling with hypotension. Low-dose
norepinephrine infusion (0.2 mg/kg/min) and ﬂuid expansion
were started. Transthoracic echocardiography showed severe left
ventricular dysfunction (left ejection fraction of 20%), with akinetic
apical and midventricular segments while basal segments were
hyperkinetic (Fig. 1A and B; Video 1). The cardiac index as esti-
mated by echocardiography was low (1.25 L/min/m2). The elec-
trocardiogram showed inverted T waves in the precordial leads.
Analysis of blood samples revealed high lactate levels (6.5 mmol/L)
and amild increase in troponin I (3.68 ng/mL). Emergency coronary
angiography was normal. The typical ventriculographic presenta-
tion suggested TTC. Because the lactate levels continued to increase
despite norepinephrine infusion, and based on the TTCts reserved.
Fig. 1. Transthoracic echocardiography (parasternal long axis view) before (end diastole (A) and end systole (B)) and after milrinone infusion (end diastole (C) and end systole (D)).
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(bolus of 50 mg/kg over 10 min then continuous infusion of
0.375 mg/kg/min), rather than dobutamine, which could theoreti-
cally worsen the cardiac catecholamine toxicity. Four hours later,
the lactate level normalized and echocardiography revealed an
improved left ventricular ejection fraction (Fig. 1C and D; Video 2).
Norepinephrine was maintained at the same dosage at admission
(0.2 mg/kg/min) and stopped a few hours after milrinone initiation.
Milrinone was administered during 48 h. No arrhythmias were
recorded. After milrinone discontinuation, echocardiography
showed complete left ventricular function recovery and the patient
was successfully weaned from mechanical ventilation.Discussion
To our knowledge, this is the ﬁrst report of a TTC complicated by
cardiogenic shock that was successfully managed with milrinone.
The major pathophysiological phenomenon involved in TTC is
considered as disproportionate catecholamine discharge in
response to stress.3 This “catecholamine rush” is thought to satu-
rate beta receptors and to literally stun the myocardium. At
supraphysiological concentrations, catecholamines could result in
beta-receptor paradoxical negative inotropic effects.5 Cardiogenic
shock is mostly treated with dobutamine or epinephrine.6 But in
TTC patients, these catecholamines could, given their beta agonist
action, worsen myocardial stunning. Milrinone is a well known
non-catecholamine inotrope that is used less than catechol-
amines.6,7 By inhibiting type III phosphodiesterase, milrinone in-
creases the calcium inﬂux and improves myocardial contraction
without any beta agonist action.7 This drug also decreases the
systemic vascular resistance and pulmonary capillary wedge
pressure.7 Furthermore there is a lower increase in the heart rate
and myocardial oxygen consumption with milrinone compared
with catecholamines.7 However, the induced peripheral vasodila-
tation may promote hypotension.
Because the lactate levels and cardiac index improved only after
starting milrinone infusion, we supposed that milrinone stabilized
the hemodynamic condition. Anyway, low-dose norepinephrinewas not sufﬁcient to explain the improvement in the cardiac index.
However, initial norepinephrine administration could have avoided
hypotension induced by milrinone. Mebazza et al suggested
norepinephrine infusion in the case of hypotension caused by
milrinone.8
Padayachee et al proposed the use of levosimendan, a calcium
sensitizer, to treat TTC presenting with cardiogenic shock.9 They
handled successfully two patients with this drug. Levosimendan
binds to the N-terminal lobe of cardiac troponin C and stabilizes the
calcium-bound conformation, resulting in sustained interaction
between actin and myosin ﬁlaments in systole and improves the
myocardial systolic function. However, levosimendan administra-
tion is also associated with vasoplegia and hypotension.10
Conclusion
TTC presenting with cardiogenic shock represents a difﬁcult
challenge in intensive care units. Considering the unique physio-
pathology of TTC, the use of catecholamines could be dangerous
and alternative inotropes such as milrinone or levosimendan
should be preferred.
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